January 12-15, 2026 | San Francisco Marriott Marquis, CA
At Evox Therapeutics, we focus on tackling genetically defined CNS disorders using exosome-based genome-editing therapeutics. Our lead programs address SCA2/ALS targeting ATXN2 and Huntington’s disease targeting MSH3